Economic Evaluation of the Randomized Aldactone Evaluation Study (RALES): Treatment of Patients with Severe Heart Failure

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cardiovascular Drugs and Therapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1023/A:1015371616135PMID 12085979
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)

  2000cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

  2000cited by this paper
• THE EFFECT OF CARVEDILOL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999influential reference
• Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure.

  1999cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Consensus recommendations for the management of chronic heart failure

  1999cited by this paper
• Estimating medical costs from incomplete follow-up data.

  1997cited by this paper
• Confidence intervals for cost-effectiveness ratios: a comparison of four methods.

  1997cited by this paper
• The epidemiology of heart failure.

  1997cited by this paper
• CONGESTIVE HEART FAILURE IN OLDER ADULTS * : Epidemiology, Pathophysiology, and Etiology of Congestive Heart Failure in Older Adults

  1997cited by this paper
• Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.

  1996cited by this paper
• The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

  1996cited by this paper
• Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial.

  1995influential reference
• Heart failure: evaluation and care of patients with left ventricular systolic dysfunction.

  1995cited by this paper
• Economic impact of heart failure in the United States: time for a different approach.

  1994cited by this paper
• Epidemiology of heart failure in the United States.

  1993cited by this paper
• The CE Plane

  1990cited by this paper
• Physician utilization of laboratory procedures to monitor outpatients with congestive heart failure.

  1989cited by this paper
• Predicting hospital-associated mortality for Medicare patients. A method for patients with stroke, pneumonia, acute myocardial infarction, and congestive heart failure.

  1988cited by this paper
• INFERENCE AND MISSING DATA

  1975cited by this paper

• Mineralocorticoid Receptor Antagonists: The Pillar Drug in Heart Failure

  2026cites this paper
• The Role of Myocardial Revascularization in Ischemic Heart Failure in the Era of Modern Optimal Medical Therapy

  2025cites this paper
• The economics of heart failure care.

  2024cites this paper
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2022cites this paper
• Economic Issues in Heart Failure in the United States.

  2022cites this paper
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2022cites this paper
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2022cites this paper
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2022cites this paper
• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.

  2020cites this paper
• Heart failure

  2020cites this paper
• Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia

  2018cites this paper
• Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review

  2018cites this paper
• Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review

  2018cites this paper
• Pharmacological interventions for heart failure in people with chronic kidney disease.

  2016cites this paper
• The matter of economic evaluations in health policy decision-making : The case of the Swedish national guidelines for heart diseases

  2015cites this paper
• Economic Evaluation of Cardiac Contractility Modulation (CCM) Therapy with the Optimizer IVs in the Management of Heart Failure Patients

  2015cites this paper
• The economics of heart failure.

  2013cites this paper
• Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.

  2013cites this paper
• Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis.

  2013cites this paper
• Economic Burden of Heart Failure in the Elderly

  2012cites this paper
• Candesartan Cilexetil

  2012cites this paper
• Compilation of cost-effectiveness evidence for different heart conditions and treatment strategies

  2011cites this paper
• Potential impact of optimal implementation of evidence-based heart failure therapies on mortality.

  2011cites this paper
• Linköping University Post Print Compilation of cost-effectiveness evidence for different heart conditions and treatment strategies

  2011cites this paper
• What are the costs of heart failure?

  2011cites this paper
• Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure

  2011cites this paper
• Costs of Inpatient Care Among Medicare Beneficiaries With Heart Failure, 2001 to 2004

  2010cites this paper
• A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.

  2010cites this paper
• Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.

  2008cites this paper
• Medical Research: What's It Worth?

  2008cites this paper
• Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy

  2008cites this paper
• Literacy and health outcomes. A systematic review of the literature

  2008cites this paper
• An introduction to dilated cardiomyopathy

  2008cites this paper
• Aldosterone antagonists in heart failure

  2007cites this paper
• Cost-Effectiveness Issues

  2007cites this paper
• Aldosterone antagonists in the treatment of heart failure.

  2006cites this paper
• Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis

  2006cites this paper
• Analytic considerations in economic evaluations of multinational cardiovascular clinical trials.

  2006influential citation
• Incorporating pharmacoeconomic and health outcomes into randomized clinical trials

  2005cites this paper
• Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.

  2005cites this paper
• Socioeconomic relevance of selected treatment strategies in patients with chronic heart failure

  2005cites this paper
• Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.

  2005cites this paper
• Eplerenone: A Selective Aldosterone Receptor Antagonist for Patients with Heart Failure

  2005cites this paper
• The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

  2004cites this paper
• Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

  2004cites this paper
• The Role of Aldosterone Antagonists in Systolic Heart Failure

  2004cites this paper
• Developments in Economic Evaluation in Health Care: A Review of HEED

  2004cites this paper
• Misprogram a PCA Pump? It's Easier than you Think: Ratio Expression for Epinephrine Injection Again Leads to Error: Tetanus Toxoid Vaccines Used for PPD: Current Nonproprietary Drug Names under Consideration by United States Adopted Names Council

  2004cites this paper
• Aldosterone receptor blockade: a therapy resurrected.

  2003cites this paper
• Design and analysis of unit cost estimation studies: How many hospital diagnoses? How many countries?

  2003cites this paper